Study guide

24.2 Polypharmacy, Deprescribing & Pressure Ulcers

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

24.2 Polypharmacy, Deprescribing & Pressure Ulcers

Key Takeaways Explain This Topic AI

Anticholinergic burden from drugs such as oxybutynin, amitriptyline and promethazine causes confusion, falls and urinary retention in older people.

STOPP/START criteria identify both potentially inappropriate prescriptions and omitted indicated treatments in older adults.

Pressure ulcer grade 3 involves full-thickness skin loss with visible subcutaneous fat, while grade 4 exposes bone, tendon or muscle.

Last updated: September 2026

4. Safe Prescribing & Polypharmacy in the Elderly

Polypharmacy (commonly defined as the concurrent use of ≥5 regular medications) is present in >40% of older inpatients, driving adverse drug reactions (ADRs), drug-drug interactions, non-adherence, delirium, and hospital readmissions.

Age-Related Pharmacokinetics & Pharmacodynamics

Pharmacokinetic Domain Physiological Change with Ageing Clinical Impact on Drug Handling High-Yield Drug Examples

Absorption Increased gastric pH (achlorhydria), delayed gastric emptying, reduced splanchnic blood flow Passive absorption largely unchanged; active transport mechanisms reduced Decreased absorption of oral iron, vitamin B12, and calcium

Distribution: Body Composition Decreased Total Body Water (TBW down by 10–15%) and reduced lean muscle mass Decreased Volume of Distribution (Vd) for hydrophilic drugs , producing higher peak serum concentrations Gentamicin, Digoxin, Lithium, Atenolol (risk of acute toxicity)

Distribution: Adipose Tissue Increased Body Fat (up by 20–40%) Increased Volume of Distribution (Vd) for lipophilic drugs , causing tissue accumulation and marked prolongation of elimination half-life Diazepam, Chlordiazepoxide, Amiodarone (prolonged sedation/ataxia)

Distribution: Protein Binding Decreased serum albumin concentration Increased free active fraction of highly protein-bound acidic drugs Phenytoin, Warfarin (heightened toxicity at normal total concentrations)

Hepatic Clearance Decreased hepatic volume (down 20–30%) and hepatic blood flow (down 20–40%) Reduced first-pass hepatic metabolism , dramatically increasing systemic bioavailability of high-extraction drugs; slowed Phase I CYP450 oxidation Morphine, Propranolol, Labetalol, Nitrates, Verapamil (require lower initial doses)

Renal Elimination Progressive sclerosis of glomeruli, loss of nephrons; GFR declines ~1 mL/min/year after age 40 Reduced renal clearance of parent drugs and active metabolites. Sarcopenia leads to low creatinine generation, keeping serum creatinine misleadingly normal! DOACs, Digoxin, Aminoglycosides, Enoxaparin, Gabapentin (must estimate CrCl via Cockcroft-Gault)

Explicit Prescribing Criteria: Beers & STOPP/START

STOPP (Screening Tool of Older Persons' Prescriptions): Identifies potentially inappropriate medications (PIMs) in older adults.

START (Screening Tool to Alert to Right Treatment): Identifies evidence-based prescribing omissions (e.g. statin post-stroke, ACE inhibitor in heart failure, bisphosphonates in severe osteoporosis).

High-Risk Drug Classes in Geriatric Practice

Anticholinergic Agents (Anticholinergic Burden [ACB] Score):

Common culprits: Amitriptyline, oxybutynin, chlorphenamine, cyclizine, hyoscine, paroxetine, prochlorperazine.

High ACB scores directly cause acute delirium, accelerated cognitive decline, dry mouth, blurred vision, acute closed-angle glaucoma, constipation, and acute urinary retention.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs):

Inhibit renal prostaglandin synthesis (PGI2, PGE2), inducing afferent arteriolar vasoconstriction and precipitating acute kidney injury (AKI).

Promote renal sodium and water retention, exacerbating congestive cardiac failure and severe hypertension.

Synergistic ulceration and life-threatening upper GI bleeding.

"The Triple Whammy": Concurrent combination of NSAID + ACE inhibitor/ARB + Diuretic , producing acute tubular necrosis via simultaneous afferent arteriolar constriction (NSAID), efferent arteriolar vasodilation (ACEi), and volume depletion (diuretic).

Benzodiazepines & Z-Drugs (Zopiclone, Zolpidem):

Exaggerated GABAergic sensitivity produces psychomotor slowing, daytime somnolence, confusion, ataxia, and a 2-fold increased risk of falls and femoral neck fractures .

Sulfonylureas (Gliclazide, Glimepiride):

Prolonged half-life in renal impairment stimulates prolonged endogenous insulin secretion, triggering severe, protracted, fatal hypoglycaemia. Gliclazide is preferred over glibenclamide (glibenclamide is strictly contraindicated due to long-acting active metabolites).

5. Pressure Ulcers: Staging & Prevention

Pressure ulcers (bedsores/pressure injuries) are localized injuries to the skin and underlying tissue, typically over bony prominences, resulting from sustained pressure, friction, or shear forces.

  • EPUAP / NPUAP / NICE Staging System EPUAP/NPUAP Pressure Ulcer Staging Classification
  • │
  • ├── CATEGORY I: Non-Blanchable Erythema of Intact Skin
  • │ └── Intact skin with non-blanching redness over bony prominence; area may be painful, firm, soft, or warm
  • │
  • ├── CATEGORY II: Partial-Thickness Skin Loss

│ └── Loss of dermis presenting as shallow open ulcer with red-pink wound bed; OR intact/ruptured serum blister

  • │
  • ├── CATEGORY III: Full-Thickness Skin Loss
  • │ └── Subcutaneous fat may be visible; bone, tendon, and muscle are NOT exposed; slough may be present
  • │
  • ├── CATEGORY IV: Full-Thickness Tissue Loss with Exposed Supporting Structures

│ └── Exposed bone, tendon, or muscle; slough or eschar often present; includes undermining/tunnelling (osteomyelitis risk)

  • │
  • ├── UNSTAGEABLE: Full-Thickness Skin or Tissue Loss — Depth Unknown

│ └── Base of ulcer completely covered by slough (yellow/tan/grey) or eschar (tan/brown/black), obscuring true depth

  • │ *Stable, dry, intact eschar on heels serves as biological cover and should NOT be debrided*
  • │
  • └── SUSPECTED DEEP TISSUE INJURY (DTI): Depth Unknown

└── Purple or maroon localized area of discoloured intact skin or blood-filled blister from underlying soft tissue shear

Risk Assessment & Evidence-Based Prevention

Risk Scoring Scales: Waterlow Score and Braden Scale evaluate sensory perception, moisture, physical activity, mobility, nutritional status, and friction/shear.

Preventative Interventions:

High-Specification Foam Mattresses: First-line for all patients at elevated risk.

Alternating-Pressure Dynamic Mattresses / Overlays: Indicated for high-risk patients (Category III/IV ulcers or severe immobility).

Scheduled Repositioning: Minimum 2- to 3-hourly repositioning schedule (e.g. 30-degree tilt) to relieve pressure on sacrum and greater trochanters.

Skin Barrier Films & Moisture Management: Prevent maceration from incontinence.

Nutritional Optimization: Ensuring adequate dietary protein (1.2–1.5 g/kg/day), caloric intake, and hydration.